Excellence in Hemoglobinopathies Research Award Program

by: Michael Saunders

The National Institutes of Health, more commonly known as the NIH, is a federal government agency operating within the United States Department of Health and Human Services that is appropriately responsible for supporting the nation's biomedical and health-related research studies.

The programs and grants of the NIH are specifically tailored to help in the achievement of its general agency mission which is to "seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability."

In keeping with this mission, the National Institutes of Health has formed a collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in an effort to establish the Excellence in Hemoglobinopathies Research Award Program wherein both agencies have agreed to financially support the creation of studies that could potentially improve high-impact multi-disciplinary basic and translational research studies in the hemoglobinopathies.

Initially, the NIH and the NHLBI will enter into a five-year cooperative agreement with the most compelling applicant who has submitted a research proposal that could potentially develop therapeutic molecules, biomarkers, or imaging modalities in the field of hemoglobinopathies.

  (continued...)

Excellence in Hemoglobinopathies Research Award Program
  Page 2

About The Author Michael Saunders is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. He also maintains Websites providing resources on artist grants and children grants.

Additional Resources

category - Health Grants

Small Business Innovation Research Phase IIB Bridge Awards
In line with this mission, the NIH has recently constituted the Small Business Innovation Research Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization Program.

---

Health Resources and Services Administration: Affordable Care Act - Immediate Facility Improvements Program
The HRSA administers health care grants to eligible individuals, in order to help them obtain safe and quality care through the Affordable Care Act Capital Development (Immediate Facility Improvements Program).

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---

Minority-Based Community Clinical Oncology Program Groups
In line with this mission, the National Institutes of Health has recently collaborated with the National Cancer Institute (NCI) in an attempt to establish the Minority-Based Community Clinical Oncology Program Groups (MBCCOP).

---